Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B

Detalhes bibliográficos
Autor(a) principal: Angelo, Ana Luiza Dias
Data de Publicação: 2013
Outros Autores: Cavalcante, Lourianne Nascimento, Abe Sandes, Kiyoko, Machado, Taisa Manuela Bonfim, Lemaire, Denise Carneiro, Malta, Fernanda, Pinho, João Renato Rebello, Lyra, Luiz Guilherme Costa, Lyra, André Castro
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFBA
Texto Completo: http://repositorio.ufba.br/ri/handle/ri/15897
Resumo: p. 1325–1332
id UFBA-2_18ba015f249d2eb63646875ff33fe3cc
oai_identifier_str oai:repositorio.ufba.br:ri/15897
network_acronym_str UFBA-2
network_name_str Repositório Institucional da UFBA
repository_id_str 1932
spelling Angelo, Ana Luiza DiasCavalcante, Lourianne NascimentoAbe Sandes, KiyokoMachado, Taisa Manuela BonfimLemaire, Denise CarneiroMalta, FernandaPinho, João Renato RebelloLyra, Luiz Guilherme CostaLyra, André CastroAngelo, Ana Luiza DiasCavalcante, Lourianne NascimentoAbe Sandes, KiyokoMachado, Taisa Manuela BonfimLemaire, Denise CarneiroMalta, FernandaPinho, João Renato RebelloLyra, Luiz Guilherme CostaLyra, André Castro2014-09-09T14:55:05Z2014-09-09T14:55:05Z20131807-5932http://repositorio.ufba.br/ri/handle/ri/15897v. 68, n. 10p. 1325–1332OBJECTIVES: Suppressor of cytokine signaling 3, myxovirus resistance protein and osteopontin gene polymorphisms may influence the therapeutic response in patients with chronic hepatitis C, and an association with IL28 might increase the power to predict sustained virologic response. Our aims were to evaluate the association between myxovirus resistance protein, osteopontin and suppressor of cytokine signaling 3 gene polymorphisms in combination with IL28B and to assess the therapy response in hepatitis C patients treated with pegylated-interferon plus ribavirin. METHOD: Myxovirus resistance protein, osteopontin, suppressor of cytokine signaling 3 and IL28B polymorphisms were analyzed by PCR-restriction fragment length polymorphism, direct sequencing and real-time PCR. Ancestry was determined using genetic markers. RESULTS: We analyzed 181 individuals, including 52 who were sustained virologic responders. The protective genotype frequencies among the sustained virologic response group were as follows: the G/G suppressor of cytokine signaling 3 (rs4969170) (62.2%); T/T osteopontin (rs2853744) (60%); T/T osteopontin (rs11730582) (64.3%); and the G/T myxovirus resistance protein (rs2071430) genotype (54%). The patients who had ≥3 of the protective genotypes from the myxovirus resistance protein, the suppressor of cytokine signaling 3 and osteopontin had a greater than 90% probability of achieving a sustained response (p<0.0001). The C/C IL28B genotype was present in 58.8% of the subjects in this group. The sustained virological response rates increased to 85.7% and 91.7% by analyzing C/C IL28B with the T/T osteopontin genotype at rs11730582 and the G/G suppressor of cytokine signaling 3 genotype, respectively. Genetic ancestry analysis revealed an admixed population. CONCLUSION: Hepatitis C genotype 1 patients who were responders to interferon-based therapy had a high frequency of multiple protective polymorphisms in the myxovirus resistance protein, osteopontin and suppressor of cytokine signaling 3 genes. The combined analysis of the suppressor of cytokine signaling 3 and IL28B genotypes more effectively predicted sustained virologic response than IL28B analysis alone.Submitted by Suelen Reis (suziy.ellen@gmail.com) on 2014-04-07T13:34:29Z No. of bitstreams: 1 10.6061clinics2013(10)06.pdf: 496812 bytes, checksum: d927f46be1656035b2fde06f6361dd1c (MD5)Approved for entry into archive by Rodrigo Meirelles (rodrigomei@ufba.br) on 2014-09-09T14:55:05Z (GMT) No. of bitstreams: 1 10.6061clinics2013(10)06.pdf: 496812 bytes, checksum: d927f46be1656035b2fde06f6361dd1c (MD5)Made available in DSpace on 2014-09-09T14:55:05Z (GMT). No. of bitstreams: 1 10.6061clinics2013(10)06.pdf: 496812 bytes, checksum: d927f46be1656035b2fde06f6361dd1c (MD5) Previous issue date: 2013http://dx.doi.org/10.6061/clinics/2013(10)06reponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAHepatitis CIL28BMxAOsteopontinSOCS3Genetic polymorphismsMyxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28BClinicsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleBrasilinfo:eu-repo/semantics/openAccessengORIGINAL10.6061clinics2013(10)06.pdf10.6061clinics2013(10)06.pdfapplication/pdf496812https://repositorio.ufba.br/bitstream/ri/15897/1/10.6061clinics2013%2810%2906.pdfd927f46be1656035b2fde06f6361dd1cMD51LICENSElicense.txtlicense.txttext/plain1345https://repositorio.ufba.br/bitstream/ri/15897/2/license.txt0d4b811ef71182510d2015daa7c8a900MD52TEXT10.6061clinics2013(10)06.pdf.txt10.6061clinics2013(10)06.pdf.txtExtracted texttext/plain37144https://repositorio.ufba.br/bitstream/ri/15897/3/10.6061clinics2013%2810%2906.pdf.txtc36a1da02ccd9638ca609f1fb076e3c7MD53ri/158972022-07-05 14:05:18.172oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-07-05T17:05:18Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false
dc.title.pt_BR.fl_str_mv Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B
dc.title.alternative.pt_BR.fl_str_mv Clinics
title Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B
spellingShingle Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B
Angelo, Ana Luiza Dias
Hepatitis C
IL28B
MxA
Osteopontin
SOCS3
Genetic polymorphisms
title_short Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B
title_full Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B
title_fullStr Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B
title_full_unstemmed Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B
title_sort Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B
author Angelo, Ana Luiza Dias
author_facet Angelo, Ana Luiza Dias
Cavalcante, Lourianne Nascimento
Abe Sandes, Kiyoko
Machado, Taisa Manuela Bonfim
Lemaire, Denise Carneiro
Malta, Fernanda
Pinho, João Renato Rebello
Lyra, Luiz Guilherme Costa
Lyra, André Castro
author_role author
author2 Cavalcante, Lourianne Nascimento
Abe Sandes, Kiyoko
Machado, Taisa Manuela Bonfim
Lemaire, Denise Carneiro
Malta, Fernanda
Pinho, João Renato Rebello
Lyra, Luiz Guilherme Costa
Lyra, André Castro
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Angelo, Ana Luiza Dias
Cavalcante, Lourianne Nascimento
Abe Sandes, Kiyoko
Machado, Taisa Manuela Bonfim
Lemaire, Denise Carneiro
Malta, Fernanda
Pinho, João Renato Rebello
Lyra, Luiz Guilherme Costa
Lyra, André Castro
Angelo, Ana Luiza Dias
Cavalcante, Lourianne Nascimento
Abe Sandes, Kiyoko
Machado, Taisa Manuela Bonfim
Lemaire, Denise Carneiro
Malta, Fernanda
Pinho, João Renato Rebello
Lyra, Luiz Guilherme Costa
Lyra, André Castro
dc.subject.por.fl_str_mv Hepatitis C
IL28B
MxA
Osteopontin
SOCS3
Genetic polymorphisms
topic Hepatitis C
IL28B
MxA
Osteopontin
SOCS3
Genetic polymorphisms
description p. 1325–1332
publishDate 2013
dc.date.issued.fl_str_mv 2013
dc.date.accessioned.fl_str_mv 2014-09-09T14:55:05Z
dc.date.available.fl_str_mv 2014-09-09T14:55:05Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufba.br/ri/handle/ri/15897
dc.identifier.issn.none.fl_str_mv 1807-5932
dc.identifier.number.pt_BR.fl_str_mv v. 68, n. 10
identifier_str_mv 1807-5932
v. 68, n. 10
url http://repositorio.ufba.br/ri/handle/ri/15897
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.country.fl_str_mv Brasil
dc.source.pt_BR.fl_str_mv http://dx.doi.org/10.6061/clinics/2013(10)06
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFBA
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Repositório Institucional da UFBA
collection Repositório Institucional da UFBA
bitstream.url.fl_str_mv https://repositorio.ufba.br/bitstream/ri/15897/1/10.6061clinics2013%2810%2906.pdf
https://repositorio.ufba.br/bitstream/ri/15897/2/license.txt
https://repositorio.ufba.br/bitstream/ri/15897/3/10.6061clinics2013%2810%2906.pdf.txt
bitstream.checksum.fl_str_mv d927f46be1656035b2fde06f6361dd1c
0d4b811ef71182510d2015daa7c8a900
c36a1da02ccd9638ca609f1fb076e3c7
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv
_version_ 1808459475160399872